Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with Opisthorchis viverrini.
Actins
/ metabolism
Alanine Transaminase
/ metabolism
Animals
Cholesterol
/ metabolism
Cricetinae
Curcumin
/ metabolism
Diet, High-Fat
Disease Models, Animal
Fructose
/ metabolism
Humans
Inflammation
/ pathology
Lipids
/ pharmacology
Liver
/ metabolism
Non-alcoholic Fatty Liver Disease
/ metabolism
Opisthorchiasis
/ complications
Opisthorchis
Triglycerides
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
04
2022
accepted:
13
09
2022
entrez:
27
9
2022
pubmed:
28
9
2022
medline:
30
9
2022
Statut:
epublish
Résumé
Comorbidity of Opisthorchis viverrini (OV) infection and nonalcoholic fatty-liver disease (NAFLD) enhances NAFLD progression to nonalcoholic steatohepatitis (NASH) by promoting severe liver inflammation and fibrosis. Here, we investigated the effect of supplementation with curcumin-loaded nanocomplexes (CNCs) on the severity of NASH in hamsters. Hamsters were placed in experimental groups as follows: fed standard chow diet (normal control, NC); fed only high-fat and high-fructose (HFF) diet; O. viverrini-infected and fed HFF diet (HFFOV); group fed with blank nanocomplexes (HFFOV+BNCs); groups fed different doses of CNCs (25, 50 and 100 mg/kg body weight: HFFOV+CNCs25; HFFOV+CNCs50; HFFOV+CNCs100, respectively) and a group given native curcumin (HFFOV+CUR). All treatment were for three months. The HFF group revealed NAFLD as evidenced by hepatic fat accumulation, ballooning, mild inflammation and little or no fibrosis. These changes were more obvious in the HFFOV group, indicating development of NASH. In contrast, in the HFFOV+CNCs50 group, histopathological features indicated that hepatic fat accumulation, cell ballooning, cell inflammation and fibrosis were lower than in other treatment groups. Relevantly, the expression of lipid-uptake genes, including fatty-acid uptake (cluster of differentiation 36), was reduced, which was associated with the lowering of alanine aminotransferase, total cholesterol and triglyceride (TG) levels. Reduced expression of an inflammation marker (high-mobility group box protein 1) and a fibrosis marker (alpha smooth-muscle actin) were also observed in the HFFOV+CNCs50 group. CNCs treatment attenuates the severity of NASH by decreasing hepatic steatosis, inflammation, and fibrosis as well as TG synthesis. CNCs mitigate the severity of NASH in this preclinical study, which indicates promise for future use in patients.
Sections du résumé
BACKGROUND
Comorbidity of Opisthorchis viverrini (OV) infection and nonalcoholic fatty-liver disease (NAFLD) enhances NAFLD progression to nonalcoholic steatohepatitis (NASH) by promoting severe liver inflammation and fibrosis. Here, we investigated the effect of supplementation with curcumin-loaded nanocomplexes (CNCs) on the severity of NASH in hamsters.
METHODOLOGY
Hamsters were placed in experimental groups as follows: fed standard chow diet (normal control, NC); fed only high-fat and high-fructose (HFF) diet; O. viverrini-infected and fed HFF diet (HFFOV); group fed with blank nanocomplexes (HFFOV+BNCs); groups fed different doses of CNCs (25, 50 and 100 mg/kg body weight: HFFOV+CNCs25; HFFOV+CNCs50; HFFOV+CNCs100, respectively) and a group given native curcumin (HFFOV+CUR). All treatment were for three months.
RESULTS
The HFF group revealed NAFLD as evidenced by hepatic fat accumulation, ballooning, mild inflammation and little or no fibrosis. These changes were more obvious in the HFFOV group, indicating development of NASH. In contrast, in the HFFOV+CNCs50 group, histopathological features indicated that hepatic fat accumulation, cell ballooning, cell inflammation and fibrosis were lower than in other treatment groups. Relevantly, the expression of lipid-uptake genes, including fatty-acid uptake (cluster of differentiation 36), was reduced, which was associated with the lowering of alanine aminotransferase, total cholesterol and triglyceride (TG) levels. Reduced expression of an inflammation marker (high-mobility group box protein 1) and a fibrosis marker (alpha smooth-muscle actin) were also observed in the HFFOV+CNCs50 group.
CONCLUSION
CNCs treatment attenuates the severity of NASH by decreasing hepatic steatosis, inflammation, and fibrosis as well as TG synthesis. CNCs mitigate the severity of NASH in this preclinical study, which indicates promise for future use in patients.
Identifiants
pubmed: 36166461
doi: 10.1371/journal.pone.0275273
pii: PONE-D-22-11833
pmc: PMC9514634
doi:
Substances chimiques
Actins
0
Lipids
0
Triglycerides
0
Fructose
30237-26-4
Cholesterol
97C5T2UQ7J
Alanine Transaminase
EC 2.6.1.2
Curcumin
IT942ZTH98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275273Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Endocrinol (Lausanne). 2020 Dec 14;11:597648
pubmed: 33384662
Toxicol Pathol. 2010 Dec;38(7 Suppl):5S-81S
pubmed: 21191096
Avicenna J Phytomed. 2016 Sep-Oct;6(5):567-577
pubmed: 27761427
J Lipid Res. 2016 Jul;57(7):1243-55
pubmed: 27220352
Nutrients. 2019 Oct 21;11(10):
pubmed: 31640183
Physiol Rep. 2018 Jul;6(14):e13789
pubmed: 30009570
J Gastroenterol. 2013 Apr;48(4):434-41
pubmed: 23397118
Toxicol Appl Pharmacol. 2016 Aug 1;304:99-109
pubmed: 27208389
Parasitol Int. 2012 Mar;61(1):208-11
pubmed: 21771664
Int Immunopharmacol. 2017 Mar;44:174-182
pubmed: 28110063
Gut Liver. 2012 Apr;6(2):149-71
pubmed: 22570745
AAPS J. 2006 Jul 07;8(3):E443-9
pubmed: 17025261
Acta Trop. 2009 Aug;111(2):181-91
pubmed: 19427296
Nutrients. 2018 Oct 19;10(10):
pubmed: 30347782
Biomed Res Int. 2017;2017:8234507
pubmed: 28770225
Environ Sci Pollut Res Int. 2020 Jul;27(20):25271-25277
pubmed: 32347481
Mol Metab. 2021 Aug;50:101111
pubmed: 33160101
Int J Mol Sci. 2021 Feb 26;22(5):
pubmed: 33652942
J Adv Res. 2021 Jun 08;34:109-122
pubmed: 35024184
Am J Trop Med Hyg. 2008 Apr;78(4):564-73
pubmed: 18385350
Infect Dis Poverty. 2019 Mar 20;8(1):18
pubmed: 30890188
Ann Hepatol. 2018 Aug 24;17(5):802-809
pubmed: 30145559
Trends Parasitol. 2012 Oct;28(10):395-407
pubmed: 22947297
Plant Foods Hum Nutr. 2017 Mar;72(1):1-12
pubmed: 27995378
Front Endocrinol (Lausanne). 2020 Nov 26;11:597583
pubmed: 33324348
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Korean J Parasitol. 2013 Dec;51(6):703-10
pubmed: 24516277
Am J Trop Med Hyg. 2019 Nov;101(5):1161-1169
pubmed: 31482785
Toxicol Rep. 2021 Jun 30;8:1346-1357
pubmed: 34277359
J Biomed Res. 2013 Jan;27(1):1-13
pubmed: 23554788
Front Pharmacol. 2020 May 12;11:601
pubmed: 32477116
Nutr Metab (Lond). 2019 Jan 28;16:8
pubmed: 30705687
Cell Metab. 2010 May 5;11(5):402-11
pubmed: 20444420
Nutrients. 2019 Nov 08;11(11):
pubmed: 31717261
Nanomedicine. 2016 Jan;12(1):21-32
pubmed: 26542278
Nat Rev Dis Primers. 2015 Dec 17;1:15080
pubmed: 27188459
J Hepatol. 2016 Sep;65(3):579-88
pubmed: 27261415
BMC Cancer. 2015 Jun 09;15:459
pubmed: 26054405
Evid Based Complement Alternat Med. 2020 Jul 17;2020:2892917
pubmed: 32724322
Ann Hepatol. 2017 Oct 16;16(6):835-841
pubmed: 29055920
Hepatology. 2012 Nov;56(5):1751-9
pubmed: 22707395
Front Med (Lausanne). 2021 Jun 30;8:691696
pubmed: 34277666
BMJ Open. 2017 Jul 10;7(7):e016914
pubmed: 28698350
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752
pubmed: 32413340
Annu Rev Nutr. 2014;34:281-303
pubmed: 24850384
Front Oncol. 2020 Sep 08;10:1788
pubmed: 33014877